Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-04-15 | Intervacc | Notice of Annual General Meeting in Intervacc AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Notice of Annual General Meeting in Intervacc AB (publ)The Board of Directors has resolved that shareholders shall have the right to exercise their voting rights in advance through postal voting pursuant to Chapter 7, Section 4 a of the Swedish Companies Act and the Company’s Articles of Associations. Therefore, shareholders may choose to exercise their voting rights at the AGM by attending by postal voting, in person or through a proxy. Participation in person Shareholders who wish to participate in the AGM in person must: − both be registered by own name (not nominee registered), in the register of shareholders maintained by Euroclear Sweden AB as per Monday 6 May 2024, − and notify their intention to participate to the Company in accordance with the instructions below, no later than Wednesday 8 May 2024. Shareholders who wish to participate at the AGM in person must submit their notice to participate through a digital form which will be available at the Company’s website, www.intervacc.se. Notification of participation may also be submitted to the Company at the address Intervacc AB (publ), att: Annual General Meeting, Box 112, 129 22 Hägersten, or through e-mail to Participation by postal voting Shareholders who wish to participate in the AGM by postal voting must: − both be registered by own name (not nominee registered), in the register of shareholders maintained by Euroclear Sweden AB as per Monday 6 May 2024, − and notify their intention to participate by submitting their postal vote in accordance with the instructions below, no later than Wednesday 8 May 2024. Shareholders may exercise their voting rights at the AGM by voting in advance through digital postal voting. For such voting, shareholders must use a digital form which will be available at the Company’s website, www.intervacc.se. Shareholders who do not wish to vote through digital postal voting, may contact the Company to receive a postal voting form that can be filled in by hand and sent to the Company by e-mail to Those who wish to withdraw a submitted postal vote and instead exercise their voting rights by participating at the AGM in person or through a proxy must give notice thereof to the AGM’s secretariat prior to the opening of the AGM. Participation by proxy Shareholders who are represented by proxy must issue a written, signed and dated power of attorney. The power of attorney in the original form shall be submitted to the Company at the above address well in advance of the AGM. A proxy form is available at the Company’s website, www.intervacc.se. If the shareholder is a legal entity, a certificate of registration (or corresponding authorisation documents for a foreign legal entity) must be attached to the form. Nominee-registered shares For shareholders who have their shares nominee-registered through a bank or other nominee, the following applies in order to be entitled to participate in the meeting. In addition to giving notice of participation (or by submitting their postal vote), such shareholder must re-register its shares in its own name so that the shareholder is registered in the share register maintained by Euroclear Sweden AB as of the record date Monday 6 May 2024. Such re-registration may be temporary (so-called voting rights registration). Shareholders who wish to register their shares in their own names must, in accordance with the respective nominee’s routines, request that the nominee make such registration. Voting rights registration that have been completed by the nominee no later than Wednesday 8 May 2024 will be considered when preparing the share register. Proposed agenda 1. Opening of the meeting and election of chairperson of the meeting. 8. Determination of the number of members of the Board of Directors and the number of auditors. Proposals Item 1 – Election of chairperson of the meeting The Nomination Committee has been appointed in accordance with the principles adopted by the Annual General Meeting 2022 and has, ahead of the AGM, consisted of Magnus Lundberg (appointed by an ownership group consisting of Håkan Björklund and Magnus Lundberg), Christian Rudbäck (appointed by an ownership group consisting of Jan-Ingmar Flock, NR Bergman Holding AB, Kenneth Janzon, Christian Rudbäck and Johan Virgin) and Björn Sjöstrand. The Nomination Committee proposes that Per Hedman, Cirio Advokatbyrå, should be appointed chairperson of the AGM. Item 7.b – Appropriation of the Company’s profit or loss according to the adopted balance sheet The Board of Directors proposes that no dividend shall be paid for the financial year 2023, and that the result shall be balanced in a new account. Item 8 – Determination of the number of members of the Board of Directors and the number of auditors The Nomination Committee proposes that the number of Board members, elected by the AGM, shall be seven, without any deputies, and that the number of auditors shall be one. Item 9 – Determination of the fees to be paid to the Board of Directors and the auditors The Nomination Committee proposes that the fees to the Board of Directors shall be paid with SEK 280,000 for the Board of Directors’ chairperson and SEK 130,000 to each of the other Board members. The Nomination Committee further proposes that fees to the auditor shall be paid according to the current account. Item 10 – Election of members of the Board of Directors and auditor The Nomination Committee proposes that the AGM resolves to re-elect Håkan Björklund, Lisen Bratt Fredricson, Jan-Ingmar Flock, Lennart Johansson and Camilla Ramfelt McCarthy, and to elect Mathias Uhlen and Emil Billbäck as Board members for the period up to and including the next AGM. The Nomination Committee proposes that the AGM resolves to re-elect Håkan Björklund as the Board of Directors’ chairperson for the period up to and including the next AGM. Mathias Uhlen, born 1954, research protein science and precision medicine, has a PhD in biotechnology and works as a professor at both Karolinska Institutet and the Royal Institute of Technology in Stockholm. Mathias Uhlen has previously held board assignments for the National committee for Biochemistry, HUPO international Antibody Initiative (HAI) and European Federation Biotechnology (EFB) and has an ongoing board assignment in the Swedish Research Council. Furthermore, Mathias Ulen is the editor for several journals, such as Protein Engineering, Design and Selection (PEDS) and Cell Systems. Mathias Uhlen is also independent in relation to the Company, management and the Company’s major shareholders. Emil Billbäck, born 1970, has a B.Sc. in Business Administration, Economics and Marketing and more than 25 years of experience in the life science industry, of which 11 years in senior leadership positions under private equity ownership. Emil Billbäck is currently the CEO of Bonesupport AB, a leading company in orthobiology, bone healing and infection treatment. Emil Billbäck is also independent in relation to the Company, management and the Company’s major shareholders. Information about the other proposed members of the Board of Directors is available at the Company’s website, www.intervacc.se. The Nomination Committee proposes that the registered public accounting firm Öhrlings PricewaterhouseCoopers AB is re-elected as the Company’s auditor for the period up to and including the next AGM. Öhrlings PricewaterhouseCoopers AB has announced that they intend to appoint the Authorised Public Accountant Niclas Bergenmo as auditor in charge. Item 11 – Resolution regarding authorisation for the Board of Directors to increase the share capital through new issues of shares, warrants and/or convertibles The Board of Directors proposes that the AGM resolves to authorise the Board of Directors, within the limits of the Articles of Association, with or without deviation from the shareholders’ preferential rights, on one or more occasions, until the next AGM, resolve to increase the Company’s share capital through issues of new shares, warrants and/or convertibles in the Company. The purpose of the authorisation and the reasons for any deviation from the shareholders’ preferential rights, is that the issues may be executed in order to increase the Company’s financial flexibility. The total number of shares covered by such new issues may correspond to a total of no more than ten (10) percent of the shares in the Company, based on the total number of shares in the Company at the time of the AGM 2024. The issues shall be made at a market price, subject to a market discount, where applicable, and payment may, in addition to cash payment, be made in kind or by set-off, or otherwise with conditions. For a valid resolution in accordance with this item the support of shareholders representing at least two-thirds of the number of votes and shares represented at the AGM is required. The Board of Directors, the CEO or the person appointed by the Board of Directors shall be authorised to make such minor adjustments and clarifications to the AGM’s resolutions that may be required in order to register the resolutions with the Swedish Companies Registration Office. Item 12 – Resolution on a) amendment of the Articles of Association regarding the limits of the share capital, and b) reduction of the share capital for allocation to non-restricted equity In order to improve the relation between restricted share capital and unrestricted equity, the Board of Directors proposes that the AGM resolves on a reduction of the share capital, without retirement of shares, for allocation to non-restricted equity and related amendment of the limits for the share capital in the Company’s Articles of Association in accordance with what is stated below. a) amendment of the Articles of Association regarding the limits of the share capital To enable the reduction of the share capital proposed under item 12 b) below, the Board of Directors proposes that the limits for the share capital under § 4 of the Company’s Articles of Association are amended as follows. +————+—————————————————————-+ b)reduction of the share capital for allocation to non-restricted equity The Board of Directors proposes that the AGM resolves to reduce the Company’s share capital by SEK 136,325,285.444635. The reduction shall be carried out without retirement of shares. The reduction amount shall be allocated to non-restricted equity. After the reduction, the Company’s share capital will amount to SEK 15,147,252.80 divided into 75,736,264 shares, each with a quota value of SEK 0.20. The implementation of the resolution regarding reduction of the share capital for allocation to non-restricted equity requires authorisation from the Swedish Companies Registration Office. Resolution in accordance with items a) – b) above shall be adopted as one resolution. For a valid resolution, in accordance with this item the support of shareholders representing at least two-thirds of the number of votes and shares represented at the AGM is required. The Board of Directors, the CEO or the person appointed by the Board of Directors shall be authorised to make such minor adjustments and clarifications to the AGM’s resolutions that may be required in order to register the resolutions with the Swedish Companies Registration Office. Disclosures at the AGM The Board of Directors and the CEO shall, if requested by any shareholder and if the Board of Directors is of the opinion that it can be done without causing material harm to the Company, at the AGM provide disclosures about conditions that may impact assessment of an item on the agenda, about conditions that may impact assessment of the Company’s financial situation, and about the Company’s relationship with another group company. Documentation Annual report, auditor’s report and other documents that are to be made available in accordance with the Swedish Companies Act, will be available at the Company on Västertorpsvägen 135, 129 22 Hägersten, and at the Company’s website, www.intervacc.se, not later than Wednesday 24 April 2024. The documents will also be sent free of charge to shareholders who so request and provide their postal address. Processing of personal data For information on how your personal data is processed in connection to the AGM see the privacy policy available on Euroclear Sweden AB’s website: https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf . Hägersten in April 2024 Intervacc AB (publ) The Board of Directors Contact information for Certified Adviser Eminova Fondkommission AB E-mail: |
||||
2024-04-15 | Intervacc | Kallelse till årsstämma i Intervacc AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-10 | Intervacc | Intervacc publishes the 2023 Annual Report | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-10 | Intervacc | Intervacc publicerar årsredovisning för 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-04 | Intervacc | Intervacc announces changes in the Nomination Committee | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-04 | Intervacc | Intervacc offentliggör förändringar i valberedningen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-28 | Intervacc | Jonas Sohlman ny VD för Intervacc AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-28 | Intervacc | Jonas Sohlman appointed as new CEO for Intervacc | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-22 | Intervacc | Intervacc announces changes in dates for AGM and report for the first quarter 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-22 | Intervacc | Intervacc tidigarelägger årsstämma och rapport för första kvartalet 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-21 | Penser Access by Carnegie | Penser Access by Carnegie: Intervacc - Behöver visa tillväxt | Pressreleaser | Visa Stäng |
|
||||
2024-02-16 | Intervacc | Intervacc: Year-end report January - December 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-16 | Intervacc | Intervacc: Bokslutskommuniké januari - december 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-13 | Intervacc | Intervacc: Inbjudan till telefonkonferens och audiocast i samband med bokslutskommuniké | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-13 | Intervacc | Intervacc: Invitation to conference call and audiocast in connection with the year-end report | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-07 | Intervacc | Intervacc awarded prestigious Eurostars grant to advance their new prototype vaccine against Streptococcus suis infection in pigs | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-07 | Intervacc | Intervaccs tilldelas prestigefullt bidrag från Eurostars för vidareutveckling av sitt prototypvaccin till gris | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-21 | Intervacc | Intervacc announces changes in the Nomination Committee | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-21 | Intervacc | Förändringar av valberedningen i Intervacc | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-11 | Intervacc | Intervacc: The National Equestrian Centre at Flyinge to host European expert meeting on the use of vaccination to prevent strangles in horses | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-11 | Intervacc | Intervacc: Europas ledande experter inom kvarka träffas vid riksanläggningen i Flyinge för att dela de senaste framstegen kring smittskydd och vaccination | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-23 | Intervacc | Kommuniké från extra bolagsstämma i Intervacc | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-23 | Intervacc | Report from Extraordinary General Meeting in Intervacc | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-22 | Intervacc | U.S. patent approval for Intervacc's vaccine against infections caused by Streptococcus suis | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-22 | Intervacc | Intervacc beviljas patent i USA för vaccin mot infektioner orsakade av Streptococcus suis | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-17 | Penser Access | Penser Access: IVACC Q3 2023 - Intervacc | Pressreleaser | Visa Stäng |
|
||||
2023-11-16 | Intervacc | Intervacc: Delårsrapport januari - september 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-16 | Intervacc | Intervacc: Interim report January - September 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-15 | Intervacc | Inbjudan till webcast i samband med Intervaccs delårsrapport för tredje kvartalet, 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-15 | Intervacc | Invitation to conference call with presentation of Intervacc's Interim report for the third quarter, 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-30 | Intervacc | Valberedning utsedd i Intervacc | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-30 | Intervacc | Nomination Committee appointed in Intervacc | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-19 | Intervacc | Intervacc: NOTICE OF EXTRAORDINARY GENERAL MEETING IN INTERVACC AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-19 | Intervacc | Intervacc: KALLELSE TILL EXTRA BOLAGSSTÄMMA I INTERVACC AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-01 | Penser Access | Penser Access: IVACC Q2’23 - Intervacc | Pressreleaser | Visa Stäng |
|
||||
2023-08-31 | Intervacc | Intervacc: Delårsrapport januari - juni 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-31 | Intervacc | Intervacc: Interim report January - June 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-21 | Intervacc | Andreas Andersson steps down as President and CEO. Jonas Sohlman has been appointed acting President and CEO for Intervacc | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-21 | Intervacc | Andreas Andersson slutar som VD och koncernchef - Jonas Sohlman har utsetts som tillförordnad VD och koncernchef för Intervacc | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-17 | Intervacc | Intervacc beviljas bidrag för att utveckla tillverkningsprocessen för ett prototypvaccin för grisar | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-17 | Intervacc | Intervacc awarded grant to optimise production processes for a fusion protein, which is one component of a prototype vaccine for pigs | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-11 | Intervacc | Intervacc to collaborate with Testa Center to optimise production processes for their prototype vaccine for pigs | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-11 | Intervacc | Intervaccs beviljas medel för uppstartsfasen i ett utvecklingsprojekt som avser att ta fram tillverkningsprocesser för ett prototypvaccin mot Streptococcus suis infektioner hos gris | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-10 | Intervacc | Intervacc ställer ut på Falsterbo Horse Show | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-08 | Intervacc | Intervacc offentliggör utfall i den fullt säkerställda företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-08 | Intervacc | Intervacc announces the outcome of the fully secured rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-07 | Intervacc | Kommuniké från årsstämman i Intervacc AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-07 | Intervacc | Report from Annual General Meeting in Intervacc | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-22 | Intervacc | Intervacc AB (publ) publishes prospectus in connection with a fully covered rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-22 | Intervacc | Intervacc AB (publ) offentliggör prospekt i samband med fullt säkerställd företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-17 | Intervacc | Intervacc: Europeiska läkemedelsmyndigheten (EMA) godkänner förlängning av hållbarheten för Strangvac, ett vaccin mot kvarka, till 33 månader | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-17 | Intervacc | Intervacc: The European Medicines Agency (EMA) approves extention of shelf life for Strangvac, a vaccine against equine strangles, to 33 months | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-15 | Penser Access | Penser Access: Villkoren för företrädesemissionen kommunicerade - Intervacc | Pressreleaser | Visa Stäng |
|
||||
2023-05-11 | Intervacc | Styrelsen i Intervacc har beslutat om en fullt säkerställd företrädesemission om cirka 104 miljoner kronor | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-11 | Intervacc | The Board of Directors in Intervacc has resolved on a fully covered rights issue of approximately SEK 104 million | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-08 | Intervacc | Intervacc: Veterinary Medicines Directorate (VMD) extends the shelf life for Strangvac, a vaccine against equine strangles, to 33 months | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-08 | Intervacc | Intervacc: Veterinary Medicines Directorate (VMD) förlänger hållbarheten för Strangvac, ett vaccin mot kvarka, till 33 månader i Storbritannien | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-05 | Intervacc | Intervacc: CORRECTION: NOTICE OF ANNUAL GENERAL MEETING IN INTERVACC AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-05 | Intervacc | Intervacc: RÄTTELSE: KALLELSE TILL ÅRSSTÄMMA I INTERVACC AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-05 | Intervacc | Intervacc: KALLELSE TILL ÅRSSTÄMMA I INTERVACC AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-05 | Intervacc | Intervacc: NOTICE OF ANNUAL GENERAL MEETING IN INTERVACC AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-05 | Intervacc | Report from Extraordinary General Meeting in Intervacc | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-05 | Intervacc | Kommuniké från extra bolagsstämma i Intervacc AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-04 | Penser Access | Penser Access: Försäljningsstarten tar längre tid än väntat - Intervacc | Pressreleaser | Visa Stäng |
|
||||
2023-05-03 | Intervacc | Intervacc: Interim report January - March 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-03 | Intervacc | Intervacc: Delårsrapport januari - mars 2023 | Rapporter | Ladda ner | Visa Stäng |
|